Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. (ALPN) Stock Competitors & Peer Comparison
See (ALPN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALPN | $64.97 | +0.02% | 4.5B | -101.52 | -$0.64 | N/A |
| VRTX | $469.34 | -1.84% | 119.2B | 31.04 | $15.12 | N/A |
| REGN | $745.77 | -0.11% | 77.5B | 18.00 | $41.44 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $700.45 | -1.19% | 43.3B | 35.76 | $19.59 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $313.41 | -1.20% | 41.6B | 135.68 | $2.31 | N/A |
| INSM | $139.50 | -0.01% | 30.1B | -21.73 | -$6.42 | N/A |
| UTHR | $536.12 | +0.62% | 23.5B | 19.26 | $27.83 | N/A |
| BNTX | $91.19 | +1.21% | 22.9B | -32.80 | -$2.78 | N/A |
Stock Comparison
ALPN vs VRTX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, VRTX has a market cap of 119.2B. Regarding current trading prices, ALPN is priced at $64.97, while VRTX trades at $469.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas VRTX's P/E ratio is 31.04. In terms of profitability, ALPN's ROE is -0.13%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ALPN is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check VRTX's competition here
ALPN vs REGN Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, REGN has a market cap of 77.5B. Regarding current trading prices, ALPN is priced at $64.97, while REGN trades at $745.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas REGN's P/E ratio is 18.00. In terms of profitability, ALPN's ROE is -0.13%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ALPN is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check REGN's competition here
ALPN vs VRNA Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ALPN is priced at $64.97, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ALPN's ROE is -0.13%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, ALPN is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check VRNA's competition here
ALPN vs ARGX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ARGX has a market cap of 43.3B. Regarding current trading prices, ALPN is priced at $64.97, while ARGX trades at $700.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ARGX's P/E ratio is 35.76. In terms of profitability, ALPN's ROE is -0.13%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, ALPN is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ARGX's competition here
ALPN vs SGEN Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ALPN is priced at $64.97, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ALPN's ROE is -0.13%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ALPN is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check SGEN's competition here
ALPN vs ALNY Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ALNY has a market cap of 41.6B. Regarding current trading prices, ALPN is priced at $64.97, while ALNY trades at $313.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ALNY's P/E ratio is 135.68. In terms of profitability, ALPN's ROE is -0.13%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, ALPN is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ALNY's competition here
ALPN vs INSM Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, INSM has a market cap of 30.1B. Regarding current trading prices, ALPN is priced at $64.97, while INSM trades at $139.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas INSM's P/E ratio is -21.73. In terms of profitability, ALPN's ROE is -0.13%, compared to INSM's ROE of -1.68%. Regarding short-term risk, ALPN is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check INSM's competition here
ALPN vs UTHR Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, UTHR has a market cap of 23.5B. Regarding current trading prices, ALPN is priced at $64.97, while UTHR trades at $536.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas UTHR's P/E ratio is 19.26. In terms of profitability, ALPN's ROE is -0.13%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ALPN is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check UTHR's competition here
ALPN vs BNTX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, ALPN is priced at $64.97, while BNTX trades at $91.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BNTX's P/E ratio is -32.80. In terms of profitability, ALPN's ROE is -0.13%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, ALPN is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check BNTX's competition here
ALPN vs MRNA Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MRNA has a market cap of 20.8B. Regarding current trading prices, ALPN is priced at $64.97, while MRNA trades at $52.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MRNA's P/E ratio is -7.24. In terms of profitability, ALPN's ROE is -0.13%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, ALPN is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MRNA's competition here
ALPN vs BGNE Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ALPN is priced at $64.97, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ALPN's ROE is -0.13%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, ALPN is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check BGNE's competition here
ALPN vs ROIV Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ROIV has a market cap of 20.1B. Regarding current trading prices, ALPN is priced at $64.97, while ROIV trades at $28.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ROIV's P/E ratio is -23.98. In terms of profitability, ALPN's ROE is -0.13%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, ALPN is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ROIV's competition here
ALPN vs RPRX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RPRX has a market cap of 19.6B. Regarding current trading prices, ALPN is priced at $64.97, while RPRX trades at $45.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RPRX's P/E ratio is 25.65. In terms of profitability, ALPN's ROE is -0.13%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, ALPN is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check RPRX's competition here
ALPN vs RVMD Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RVMD has a market cap of 18.8B. Regarding current trading prices, ALPN is priced at $64.97, while RVMD trades at $94.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RVMD's P/E ratio is -15.94. In terms of profitability, ALPN's ROE is -0.13%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, ALPN is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check RVMD's competition here
ALPN vs DNA-WT Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ALPN is priced at $64.97, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ALPN's ROE is -0.13%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, ALPN is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check DNA-WT's competition here
ALPN vs INCY Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, INCY has a market cap of 18.4B. Regarding current trading prices, ALPN is priced at $64.97, while INCY trades at $92.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas INCY's P/E ratio is 14.64. In terms of profitability, ALPN's ROE is -0.13%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ALPN is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check INCY's competition here
ALPN vs GMAB Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, GMAB has a market cap of 16.1B. Regarding current trading prices, ALPN is priced at $64.97, while GMAB trades at $26.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas GMAB's P/E ratio is 16.97. In terms of profitability, ALPN's ROE is -0.13%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, ALPN is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check GMAB's competition here
ALPN vs ASND Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ASND has a market cap of 13.9B. Regarding current trading prices, ALPN is priced at $64.97, while ASND trades at $225.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ASND's P/E ratio is -51.71. In terms of profitability, ALPN's ROE is -0.13%, compared to ASND's ROE of +1.28%. Regarding short-term risk, ALPN is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ASND's competition here
ALPN vs BBIO Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BBIO has a market cap of 13.5B. Regarding current trading prices, ALPN is priced at $64.97, while BBIO trades at $69.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BBIO's P/E ratio is -18.36. In terms of profitability, ALPN's ROE is -0.13%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, ALPN is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check BBIO's competition here
ALPN vs KRTX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ALPN is priced at $64.97, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ALPN's ROE is -0.13%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ALPN is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check KRTX's competition here
ALPN vs SMMT Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, SMMT has a market cap of 12B. Regarding current trading prices, ALPN is priced at $64.97, while SMMT trades at $16.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas SMMT's P/E ratio is -11.19. In terms of profitability, ALPN's ROE is -0.13%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, ALPN is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check SMMT's competition here
ALPN vs IONS Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, IONS has a market cap of 11.8B. Regarding current trading prices, ALPN is priced at $64.97, while IONS trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas IONS's P/E ratio is -29.91. In terms of profitability, ALPN's ROE is -0.13%, compared to IONS's ROE of -0.69%. Regarding short-term risk, ALPN is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check IONS's competition here
ALPN vs RNAM Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ALPN is priced at $64.97, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ALPN's ROE is -0.13%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ALPN is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check RNAM's competition here
ALPN vs BMRN Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, ALPN is priced at $64.97, while BMRN trades at $58.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BMRN's P/E ratio is 32.51. In terms of profitability, ALPN's ROE is -0.13%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, ALPN is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check BMRN's competition here
ALPN vs EXEL Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, EXEL has a market cap of 11.1B. Regarding current trading prices, ALPN is priced at $64.97, while EXEL trades at $41.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas EXEL's P/E ratio is 14.68. In terms of profitability, ALPN's ROE is -0.13%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, ALPN is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check EXEL's competition here
ALPN vs JAZZ Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, JAZZ has a market cap of 11B. Regarding current trading prices, ALPN is priced at $64.97, while JAZZ trades at $178.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas JAZZ's P/E ratio is -30.57. In terms of profitability, ALPN's ROE is -0.13%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, ALPN is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check JAZZ's competition here
ALPN vs MDGL Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MDGL has a market cap of 10.1B. Regarding current trading prices, ALPN is priced at $64.97, while MDGL trades at $444.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MDGL's P/E ratio is -34.62. In terms of profitability, ALPN's ROE is -0.13%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, ALPN is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MDGL's competition here
ALPN vs RXDX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ALPN is priced at $64.97, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ALPN's ROE is -0.13%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ALPN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check RXDX's competition here
ALPN vs IMGN Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ALPN is priced at $64.97, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ALPN's ROE is -0.13%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ALPN is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check IMGN's competition here
ALPN vs IBRX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, IBRX has a market cap of 8.6B. Regarding current trading prices, ALPN is priced at $64.97, while IBRX trades at $8.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas IBRX's P/E ratio is -22.08. In terms of profitability, ALPN's ROE is -0.13%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, ALPN is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check IBRX's competition here
ALPN vs BPMC Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ALPN is priced at $64.97, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ALPN's ROE is -0.13%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, ALPN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check BPMC's competition here
ALPN vs CERE Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ALPN is priced at $64.97, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CERE's P/E ratio is -16.47. In terms of profitability, ALPN's ROE is -0.13%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ALPN is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CERE's competition here
ALPN vs AXSM Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, AXSM has a market cap of 8B. Regarding current trading prices, ALPN is priced at $64.97, while AXSM trades at $156.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas AXSM's P/E ratio is -42.41. In terms of profitability, ALPN's ROE is -0.13%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, ALPN is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check AXSM's competition here
ALPN vs TECH Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, TECH has a market cap of 8B. Regarding current trading prices, ALPN is priced at $64.97, while TECH trades at $50.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas TECH's P/E ratio is 95.94. In terms of profitability, ALPN's ROE is -0.13%, compared to TECH's ROE of +0.04%. Regarding short-term risk, ALPN is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check TECH's competition here
ALPN vs PCVX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, ALPN is priced at $64.97, while PCVX trades at $54.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas PCVX's P/E ratio is -9.69. In terms of profitability, ALPN's ROE is -0.13%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, ALPN is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check PCVX's competition here
ALPN vs ARWR Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ARWR has a market cap of 7.7B. Regarding current trading prices, ALPN is priced at $64.97, while ARWR trades at $55.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ARWR's P/E ratio is 34.41. In terms of profitability, ALPN's ROE is -0.13%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, ALPN is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ARWR's competition here
ALPN vs ABVX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ABVX has a market cap of 7.6B. Regarding current trading prices, ALPN is priced at $64.97, while ABVX trades at $115.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ABVX's P/E ratio is -22.38. In terms of profitability, ALPN's ROE is -0.13%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, ALPN is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ABVX's competition here
ALPN vs HALO Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, HALO has a market cap of 7.5B. Regarding current trading prices, ALPN is priced at $64.97, while HALO trades at $63.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas HALO's P/E ratio is 24.87. In terms of profitability, ALPN's ROE is -0.13%, compared to HALO's ROE of +0.93%. Regarding short-term risk, ALPN is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check HALO's competition here
ALPN vs MTSR Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ALPN is priced at $64.97, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ALPN's ROE is -0.13%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ALPN is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MTSR's competition here
ALPN vs CYTK Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CYTK has a market cap of 7.4B. Regarding current trading prices, ALPN is priced at $64.97, while CYTK trades at $60.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CYTK's P/E ratio is -9.18. In terms of profitability, ALPN's ROE is -0.13%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, ALPN is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CYTK's competition here
ALPN vs KRYS Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, KRYS has a market cap of 7.2B. Regarding current trading prices, ALPN is priced at $64.97, while KRYS trades at $247.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas KRYS's P/E ratio is 36.20. In terms of profitability, ALPN's ROE is -0.13%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ALPN is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check KRYS's competition here
ALPN vs NUVL Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, NUVL has a market cap of 7.2B. Regarding current trading prices, ALPN is priced at $64.97, while NUVL trades at $97.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas NUVL's P/E ratio is -16.74. In terms of profitability, ALPN's ROE is -0.13%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, ALPN is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check NUVL's competition here
ALPN vs MRUS Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ALPN is priced at $64.97, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ALPN's ROE is -0.13%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ALPN is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check MRUS's competition here
ALPN vs ACLX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ALPN is priced at $64.97, while ACLX trades at $114.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ACLX's P/E ratio is -28.11. In terms of profitability, ALPN's ROE is -0.13%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ALPN is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ACLX's competition here
ALPN vs RETA Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ALPN is priced at $64.97, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RETA's P/E ratio is -66.29. In terms of profitability, ALPN's ROE is -0.13%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ALPN is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check RETA's competition here
ALPN vs BLTE Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, ALPN is priced at $64.97, while BLTE trades at $164.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BLTE's P/E ratio is -71.04. In terms of profitability, ALPN's ROE is -0.13%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, ALPN is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check BLTE's competition here
ALPN vs KYMR Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, ALPN is priced at $64.97, while KYMR trades at $79.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas KYMR's P/E ratio is -21.42. In terms of profitability, ALPN's ROE is -0.13%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, ALPN is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check KYMR's competition here
ALPN vs PRAX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, PRAX has a market cap of 6.2B. Regarding current trading prices, ALPN is priced at $64.97, while PRAX trades at $293.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas PRAX's P/E ratio is -21.81. In terms of profitability, ALPN's ROE is -0.13%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, ALPN is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check PRAX's competition here
ALPN vs RYTM Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, ALPN is priced at $64.97, while RYTM trades at $87.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RYTM's P/E ratio is -28.10. In terms of profitability, ALPN's ROE is -0.13%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, ALPN is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check RYTM's competition here
ALPN vs PTGX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, PTGX has a market cap of 5.9B. Regarding current trading prices, ALPN is priced at $64.97, while PTGX trades at $92.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas PTGX's P/E ratio is -45.05. In terms of profitability, ALPN's ROE is -0.13%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, ALPN is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check PTGX's competition here
ALPN vs CDTX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ALPN is priced at $64.97, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ALPN's ROE is -0.13%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ALPN is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check CDTX's competition here
ALPN vs ABCM Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ALPN is priced at $64.97, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ALPN's ROE is -0.13%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ALPN is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ABCM's competition here
ALPN vs COGT Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, ALPN is priced at $64.97, while COGT trades at $34.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas COGT's P/E ratio is -15.74. In terms of profitability, ALPN's ROE is -0.13%, compared to COGT's ROE of -1.00%. Regarding short-term risk, ALPN is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check COGT's competition here
ALPN vs ISEE Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ALPN is priced at $64.97, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ALPN's ROE is -0.13%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ALPN is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ISEE's competition here
ALPN vs CGON Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CGON has a market cap of 5.4B. Regarding current trading prices, ALPN is priced at $64.97, while CGON trades at $64.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CGON's P/E ratio is -30.91. In terms of profitability, ALPN's ROE is -0.13%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ALPN is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CGON's competition here
ALPN vs PTCT Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, ALPN is priced at $64.97, while PTCT trades at $64.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas PTCT's P/E ratio is 7.52. In terms of profitability, ALPN's ROE is -0.13%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, ALPN is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check PTCT's competition here
ALPN vs CELC Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CELC has a market cap of 5.3B. Regarding current trading prices, ALPN is priced at $64.97, while CELC trades at $114.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CELC's P/E ratio is -31.04. In terms of profitability, ALPN's ROE is -0.13%, compared to CELC's ROE of -1.79%. Regarding short-term risk, ALPN is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CELC's competition here
ALPN vs FBIOX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, ALPN is priced at $64.97, while FBIOX trades at $24.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ALPN's ROE is -0.13%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ALPN is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check FBIOX's competition here
ALPN vs CAI Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CAI has a market cap of 5.1B. Regarding current trading prices, ALPN is priced at $64.97, while CAI trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CAI's P/E ratio is -5.64. In terms of profitability, ALPN's ROE is -0.13%, compared to CAI's ROE of +0.25%. Regarding short-term risk, ALPN is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CAI's competition here
ALPN vs IMVT Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, IMVT has a market cap of 5B. Regarding current trading prices, ALPN is priced at $64.97, while IMVT trades at $24.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas IMVT's P/E ratio is -9.14. In terms of profitability, ALPN's ROE is -0.13%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, ALPN is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check IMVT's competition here
ALPN vs CRSP Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CRSP has a market cap of 4.7B. Regarding current trading prices, ALPN is priced at $64.97, while CRSP trades at $48.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CRSP's P/E ratio is -7.97. In terms of profitability, ALPN's ROE is -0.13%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, ALPN is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CRSP's competition here
ALPN vs ALKS Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ALKS has a market cap of 4.6B. Regarding current trading prices, ALPN is priced at $64.97, while ALKS trades at $27.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ALKS's P/E ratio is 19.41. In terms of profitability, ALPN's ROE is -0.13%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, ALPN is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ALKS's competition here
ALPN vs XENE Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, ALPN is priced at $64.97, while XENE trades at $55.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas XENE's P/E ratio is -12.67. In terms of profitability, ALPN's ROE is -0.13%, compared to XENE's ROE of -0.56%. Regarding short-term risk, ALPN is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check XENE's competition here
ALPN vs MIRM Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MIRM has a market cap of 4.6B. Regarding current trading prices, ALPN is priced at $64.97, while MIRM trades at $90.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MIRM's P/E ratio is -192.89. In terms of profitability, ALPN's ROE is -0.13%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, ALPN is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MIRM's competition here
ALPN vs FOLD Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ALPN is priced at $64.97, while FOLD trades at $14.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas FOLD's P/E ratio is -159.67. In terms of profitability, ALPN's ROE is -0.13%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ALPN is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check FOLD's competition here
ALPN vs AKRO Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ALPN is priced at $64.97, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ALPN's ROE is -0.13%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ALPN is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check AKRO's competition here
ALPN vs TGTX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, TGTX has a market cap of 4.5B. Regarding current trading prices, ALPN is priced at $64.97, while TGTX trades at $27.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas TGTX's P/E ratio is 10.09. In terms of profitability, ALPN's ROE is -0.13%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, ALPN is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check TGTX's competition here
ALPN vs OPT Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ALPN is priced at $64.97, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas OPT's P/E ratio is -1.52. In terms of profitability, ALPN's ROE is -0.13%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ALPN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check OPT's competition here
ALPN vs ERAS Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, ALPN is priced at $64.97, while ERAS trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ERAS's P/E ratio is -31.67. In terms of profitability, ALPN's ROE is -0.13%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, ALPN is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ERAS's competition here
ALPN vs TERN Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, TERN has a market cap of 4.2B. Regarding current trading prices, ALPN is priced at $64.97, while TERN trades at $46.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas TERN's P/E ratio is -45.61. In terms of profitability, ALPN's ROE is -0.13%, compared to TERN's ROE of -0.30%. Regarding short-term risk, ALPN is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check TERN's competition here
ALPN vs MRTX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ALPN is priced at $64.97, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ALPN's ROE is -0.13%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ALPN is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MRTX's competition here
ALPN vs VKTX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, ALPN is priced at $64.97, while VKTX trades at $35.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas VKTX's P/E ratio is -11.17. In terms of profitability, ALPN's ROE is -0.13%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, ALPN is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check VKTX's competition here
ALPN vs SRRK Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, SRRK has a market cap of 4.1B. Regarding current trading prices, ALPN is priced at $64.97, while SRRK trades at $40.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas SRRK's P/E ratio is -12.16. In terms of profitability, ALPN's ROE is -0.13%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, ALPN is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check SRRK's competition here
ALPN vs LGND Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, LGND has a market cap of 4B. Regarding current trading prices, ALPN is priced at $64.97, while LGND trades at $202.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas LGND's P/E ratio is 33.10. In terms of profitability, ALPN's ROE is -0.13%, compared to LGND's ROE of +0.14%. Regarding short-term risk, ALPN is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check LGND's competition here
ALPN vs APGE Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, APGE has a market cap of 4B. Regarding current trading prices, ALPN is priced at $64.97, while APGE trades at $71.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas APGE's P/E ratio is -17.04. In terms of profitability, ALPN's ROE is -0.13%, compared to APGE's ROE of -0.37%. Regarding short-term risk, ALPN is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check APGE's competition here
ALPN vs CRNX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, ALPN is priced at $64.97, while CRNX trades at $37.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CRNX's P/E ratio is -7.57. In terms of profitability, ALPN's ROE is -0.13%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, ALPN is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CRNX's competition here
ALPN vs RYZB Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ALPN is priced at $64.97, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ALPN's ROE is -0.13%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ALPN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check RYZB's competition here
ALPN vs CBAY Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ALPN is priced at $64.97, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ALPN's ROE is -0.13%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ALPN is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CBAY's competition here
ALPN vs ADMA Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ADMA has a market cap of 3.6B. Regarding current trading prices, ALPN is priced at $64.97, while ADMA trades at $15.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ADMA's P/E ratio is 25.25. In terms of profitability, ALPN's ROE is -0.13%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, ALPN is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ADMA's competition here
ALPN vs SWTX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ALPN is priced at $64.97, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ALPN's ROE is -0.13%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, ALPN is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check SWTX's competition here
ALPN vs CNTA Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CNTA has a market cap of 3.5B. Regarding current trading prices, ALPN is priced at $64.97, while CNTA trades at $26.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CNTA's P/E ratio is -13.93. In terms of profitability, ALPN's ROE is -0.13%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, ALPN is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CNTA's competition here
ALPN vs ACAD Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, ALPN is priced at $64.97, while ACAD trades at $20.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ACAD's P/E ratio is 8.96. In terms of profitability, ALPN's ROE is -0.13%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, ALPN is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ACAD's competition here
ALPN vs CORT Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CORT has a market cap of 3.4B. Regarding current trading prices, ALPN is priced at $64.97, while CORT trades at $32.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CORT's P/E ratio is 39.21. In terms of profitability, ALPN's ROE is -0.13%, compared to CORT's ROE of +0.15%. Regarding short-term risk, ALPN is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CORT's competition here
ALPN vs KNSA Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, KNSA has a market cap of 3.4B. Regarding current trading prices, ALPN is priced at $64.97, while KNSA trades at $45.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas KNSA's P/E ratio is 61.04. In terms of profitability, ALPN's ROE is -0.13%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, ALPN is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check KNSA's competition here
ALPN vs NAMS Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, NAMS has a market cap of 3.3B. Regarding current trading prices, ALPN is priced at $64.97, while NAMS trades at $28.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas NAMS's P/E ratio is -16.64. In terms of profitability, ALPN's ROE is -0.13%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, ALPN is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check NAMS's competition here
ALPN vs DNLI Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, ALPN is priced at $64.97, while DNLI trades at $20.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas DNLI's P/E ratio is -6.93. In terms of profitability, ALPN's ROE is -0.13%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, ALPN is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check DNLI's competition here
ALPN vs LQDA Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, LQDA has a market cap of 3.2B. Regarding current trading prices, ALPN is priced at $64.97, while LQDA trades at $36.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas LQDA's P/E ratio is -25.11. In terms of profitability, ALPN's ROE is -0.13%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, ALPN is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check LQDA's competition here
ALPN vs EWTX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, EWTX has a market cap of 3.2B. Regarding current trading prices, ALPN is priced at $64.97, while EWTX trades at $29.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas EWTX's P/E ratio is -18.15. In terms of profitability, ALPN's ROE is -0.13%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, ALPN is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check EWTX's competition here
ALPN vs GPCR Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, GPCR has a market cap of 3.1B. Regarding current trading prices, ALPN is priced at $64.97, while GPCR trades at $53.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas GPCR's P/E ratio is -22.40. In terms of profitability, ALPN's ROE is -0.13%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, ALPN is less volatile compared to GPCR. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check GPCR's competition here
ALPN vs DYN Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, ALPN is priced at $64.97, while DYN trades at $17.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas DYN's P/E ratio is -5.16. In terms of profitability, ALPN's ROE is -0.13%, compared to DYN's ROE of -0.61%. Regarding short-term risk, ALPN is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check DYN's competition here
ALPN vs IDYA Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, IDYA has a market cap of 2.9B. Regarding current trading prices, ALPN is priced at $64.97, while IDYA trades at $33.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas IDYA's P/E ratio is -25.85. In terms of profitability, ALPN's ROE is -0.13%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, ALPN is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check IDYA's competition here
ALPN vs TARS Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, TARS has a market cap of 2.9B. Regarding current trading prices, ALPN is priced at $64.97, while TARS trades at $67.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas TARS's P/E ratio is -42.74. In terms of profitability, ALPN's ROE is -0.13%, compared to TARS's ROE of -0.20%. Regarding short-term risk, ALPN is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check TARS's competition here
ALPN vs MORF Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, ALPN is priced at $64.97, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MORF's P/E ratio is -14.88. In terms of profitability, ALPN's ROE is -0.13%, compared to MORF's ROE of -0.29%. Regarding short-term risk, ALPN and MORF have similar daily volatility (0.05).Check MORF's competition here
ALPN vs MOR Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, ALPN is priced at $64.97, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MOR's P/E ratio is -12.64. In terms of profitability, ALPN's ROE is -0.13%, compared to MOR's ROE of -1.84%. Regarding short-term risk, ALPN is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MOR's competition here
ALPN vs CPRX Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CPRX has a market cap of 2.9B. Regarding current trading prices, ALPN is priced at $64.97, while CPRX trades at $23.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CPRX's P/E ratio is 13.83. In terms of profitability, ALPN's ROE is -0.13%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ALPN is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CPRX's competition here
ALPN vs VERA Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, ALPN is priced at $64.97, while VERA trades at $39.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas VERA's P/E ratio is -8.58. In terms of profitability, ALPN's ROE is -0.13%, compared to VERA's ROE of -0.60%. Regarding short-term risk, ALPN is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check VERA's competition here
ALPN vs ARQT Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ARQT has a market cap of 2.8B. Regarding current trading prices, ALPN is priced at $64.97, while ARQT trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ARQT's P/E ratio is -175.00. In terms of profitability, ALPN's ROE is -0.13%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, ALPN is less volatile compared to ARQT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ARQT's competition here
ALPN vs DNTH Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, DNTH has a market cap of 2.8B. Regarding current trading prices, ALPN is priced at $64.97, while DNTH trades at $77.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas DNTH's P/E ratio is -22.50. In terms of profitability, ALPN's ROE is -0.13%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, ALPN is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check DNTH's competition here
ALPN vs KDNY Comparison March 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, ALPN is priced at $64.97, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas KDNY's P/E ratio is -12.47. In terms of profitability, ALPN's ROE is -0.13%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, ALPN is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check KDNY's competition here